SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Bartsch G, Horninger W, Klocker H et al. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58: 41724
  • 2
    Kubota Y, Ito K, Imai K, Yamanaka H. Effectiveness of mass screening for the prognosis of prostate cancer patients in Japanese communities. Prostate 2002; 50: 2629
  • 3
    Neal DE, Donovan JL. Prostate cancer: to screen or not to screen? Lancet Oncol 2000; 1: 1724
  • 4
    Voss JD, Schectman JM. Prostate cancer screening practices and beliefs. J General Intern Med 2001; 16: 8317
  • 5
    Roberts RO, Bergstralh EJ, Besse JA, Lieber MM, Jacobsen SJ. Trends and risk factors for prostate biopsy complications in the pre-PSA and PSA eras, 1980–97. Urology 2002; 59: 7984
  • 6
    Fowler JE Jr, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5–9.9 ng/ml. J Urol 2000; 163: 146770
  • 7
    Fowler JE Jr, Bigler SA, Farabaugh PB. Prospective study of cancer detection in black and white men with normal digital rectal examination but prostate specific antigen equal or greater than 4.0 ng/mL. Cancer 2002; 94: 16617
  • 8
    Hoffman RM, Gilliland FD, Eley JW et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001; 93: 38895
  • 9
    Heyns CF, Naude AM, Visser AJ et al. Early diagnosis of prostate cancer in the Western Cape. S Afr Med J 2001; 91: 67984
  • 10
    Babaian RJ, Johnston DA, Naccarato W, Ayala A, Bhadkamkar VA, Fritsche HA Jr. The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol 2001; 165: 75760
  • 11
    Eastham JA, Sartor O, Richey W, Moparty B, Sullivan J. Racial variation in prostate specific antigen in a large cohort of men without prostate cancer. J La State Med Soc 2001; 153: 1849
  • 12
    Cooney KA, Strawderman MS, Wojno KJ et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 2001; 57: 916
  • 13
    Tanguay S, Begin LR, Elhilali MM, Behlouli H, Karakiewicz PI, Aprikian AG. Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection. Urology 2002; 59: 2615
  • 14
    Vis AN, Kranse R, Roobol M, Van Der Kwast TH, Schröder FH. Serendipity in detecting disease in low prostate-specific antigen ranges. BJU Int 2002; 89: 3849
  • 15
    Luboldt HJ, Bex A, Swoboda A, Husing J, Rubben H. The Early Detection Project Group of the German Urological Association. Early detection of prostate cancer in Germany: a study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff. Eur Urol 2001; 39: 1317
  • 16
    Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol 2001; 166: 84550
  • 17
    Stewart CS, Leibovich BC, Weaver AL, Lieber MM. Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 8691
  • 18
    Kojima M, Hayakawa T, Saito T, Mitsuya H, Hayase Y. Transperineal 12-core systematic biopsy in the detection of prostate cancer. Int J Urol 2001; 8: 3017
  • 19
    Durkan GC, Sheikh N, Johnson P, Hildreth AJ, Greene DR. Improving prostate cancer detection with an extended-core transrectal ultrasonography-guided prostate biopsy protocol. BJU Int 2002; 89: 339
  • 20
    Etzioni R, Berry KM, Legler JM, Shaw P. Prostate-specific antigen testing in black and white men: an analysis of Medicare claims from 1991 to 1998. Urology 2002; 59: 2515
  • 21
    Steginga SK, Occhipinti S, McCaffrey J, Dunn J. Men's attitudes toward prostate cancer and seeking prostate-specific antigen testing. J Cancer Educ 2001; 16: 425
  • 22
    Myers RE, Hyslop T, Jennings-Dozier K et al. Intention to be tested for prostate cancer risk among African-American men. Cancer Epidemiol Biomarkers Prev 2000; 9: 13238
  • 23
    Liu L, Cozen W, Bernstein L, Ross RK, Deapen D. Changing relationship between socioeconomic status and prostate cancer incidence. J Natl Cancer Inst 2001; 93: 7059
  • 24
    Volk RJ, Cass AR. The accuracy of primary care patients’ self-reports of prostate-specific antigen testing. Am J Prev Med 2002; 22: 568
  • 25
    De Koning HJ, Auvinen A, Berenguer Sanchez A et al. European Randomized Screening for Prostate Cancer (ERSPC) Trial. International Prostate Cancer Screening Trials Evaluation Group. Large-scale randomized prostate cancer screening trials. program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 2002; 97: 23744
  • 26
    Ashford AR, Albert SM, Hoke G, Cushman LF, Miller DS, Bassett M. Prostate carcinoma knowledge, attitudes, and screening behavior among African-American men in Central Harlem, New York City. Cancer 2001; 91: 16472
  • 27
    Nijs HG, Essink-Bot ML, DeKoning HJ, Kirkels WJ, Schröder FH. Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med 2000; 22: 3126